Good panretinal photocoagulation: Time tested, evidence proven, and still the real deal in PDR

The Diabetic Retinopathy Study and Early Treatment for Diabetic Retinopathy Study have established the treatment protocols for high-risk proliferative diabetic retinopathy (HRPDR).[1,2] The image displays the regression pattern of neovascularization (NVD) following customized pan retinal photocoagulation (PRP) in HRPDR.[3]Fig. 1a shows prominent, angry looking NVD located at the optic disc. Fig. 1b demonstrates shrinkage of NVD after two sessions of PRP (1,000 single spot burns, single burn spaced, and applied to the inferior and temporal retina in each sitting, respectively). Fig. 1c shows marked regression of the NVD, 1 month after PRP. Laser treatment was delivered using an Iridex green laser and a Mainster Volk 165 lens. Laser parameters included a power of 250–400 mW, duration of 120 ms, and a spot size of 200 µm, achieving a moderate-to-severe burn intensity. Best-corrected visual acuity was 6/9 on the Snellen chart both before and after laser treatment. This sequence of images underscores the importance of timely and effective PRP in treating HR PDR.Figure 1: (a) Showing Right eye High risk PDR, (b) showing early regression of NVD post PRP, (c) Depicting a stable and well regressed PDR after 1 month of PRPAuthors’ contributions Debolina Deb: Concept, design, definition of intellectual content, literature search, data analysis, manuscript preparation, manuscript editing, and manuscript review; Prithvi Chandrakanth: Concept, design, definition of intellectual content, data acquisition, data analysis, manuscript preparation, manuscript editing, and manuscript review; Chandrakanth KS: Concept, design, definition of intellectual content, manuscript editing, and manuscript review. Declaration of patient consent The author certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in this journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed. Financial support and sponsorship: Nil. Conflicts of interest: There are no conflicts of interest.